Moffitt signs deal with Swiss firm Debiopharm - Tampa Bay Business Journal:

fusajacuxejilyp.blogspot.com
Under terms of the agreement, Debiophar m will pay Moffitt anupfront fee, as well as predefine advanced milestone payments durinb the development of the treatment, a release The payment terms were not disclosed. The agreemenf gives Debiopharm, a global biopharmaceutical group of companieds basedin Switzerland, an exclusive license to develop and commercialize Debilo 0928, a small molecule in early preclinicall development. The molecule prevents an interactio n that oftwo proteins, creating a new strategt in the fight against cancer, the releasse said. The discovery was the resulgt of collaborationbetween Drs.
Srikumar Chellappan, Said Sebtj and Nicholas Lawrence at Debio 0928 is a therapeutic strategy with the potential for targeting a wide range ofhuman cancers, Sebti, chair of the department of drug discoverty at Moffitt, said in the release. The in Tampaq is the only Florida-based cancer centeer designated as a Comprehensivs Cancer Center bythe .